Skip to main content Accessibility help
×
Hostname: page-component-78c5997874-fbnjt Total loading time: 0 Render date: 2024-11-02T19:16:37.106Z Has data issue: false hasContentIssue false

Drugs: beta-blockers

from Medical topics

Published online by Cambridge University Press:  18 December 2014

Sari D. Schwartz
Affiliation:
Uniformed Services University of the Health Sciences
David S. Krantz
Affiliation:
Uniformed Services University of the Health Sciences
Susan Ayers
Affiliation:
University of Sussex
Andrew Baum
Affiliation:
University of Pittsburgh
Chris McManus
Affiliation:
St Mary's Hospital Medical School
Stanton Newman
Affiliation:
University College and Middlesex School of Medicine
Kenneth Wallston
Affiliation:
Vanderbilt University School of Nursing
John Weinman
Affiliation:
United Medical and Dental Schools of Guy's and St Thomas's
Robert West
Affiliation:
St George's Hospital Medical School, University of London
Get access

Summary

Beta-blockers are a class of drugs that selectively compete for and inhibit binding at the beta-adrenergic subset of receptors of the sympathetic nervous system (Middlemiss et al., 1981; Patel & Turner, 1981). Beta-adrenergic receptors are primarily located in the heart and in the smooth muscle of the blood vessels and the lungs, but also exert metabolic and other effects. The beta-blockers are structurally similar to the body's adrenergic neurotransmitters, norepinephrine and epinephrine, and they exhibit their greatest effects during periods of intense sympathetic nervous system (SNS) activation. Therefore, the most common clinical use of these drugs is for the treatment of cardiovascular disorders, including hypertension and manifestations of ischaemic heart disease such as angina pectoris and cardiac arrhythmias (Frishman, 1980; Patel & Turner, 1981; Weiner, 1985).

However, since the introduction of these drugs and their wide therapeutic use, a variety of both desirable and unwanted psychological effects have been observed. One of the most frequently noted beneficial effects has been the reduction of reported anxiety by individuals in certain acutely stressful situations (e.g. performing before an audience or dental surgery) that are normally accompanied by several somatic manifestations of arousal (Frishman et al., 1981; Noyes, 1982; Elman et al., 1998). There have also been some reports that chronic beta-blocker therapy might lessen anger and irritability or ‘coronary-prone’ behaviour pattern (Schmeider et al., 1983; Krantz & Durel, 1983; Fedorets et al., 2004).

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Benschop, R. J., Jacobs, R., Sommer, B.et al. (1996). Modulation of the immunologic response to acute stress in humans by beta-blockade or benzodiazepines. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology, 10, 517–24.CrossRefGoogle Scholar
Beversdorf, D. Q., White, D. M., Chever, D. C.et al. (2002). Central beta-adrenergic modulation of cognitive flexibility. Neuroreport, 13, 2505–7.CrossRefGoogle Scholar
Blumenthal, J. A., Madden, D. J., Krantz, D. S.et al. (1988). Short-term behavioral effects of beta-adrenergic medications in men with mild hypertension. Clinical Pharmacology and Therapeutics, 43, 429–35.Google Scholar
Brousse, G., Schmitt, A., Chereau, I.et al. (2003). Interest of the use of pindolol in the treatment of depression: review. Encephale, 29, 338–50.Google Scholar
Cruickshank, J. M. (1980). The clinical importance of cardioselectivity and lipophilicity in beta blockers. American Heart Journal, 100, 160–8.CrossRefGoogle Scholar
Culic, V., Eterovic, D., Miric, D.et al. (2004). Triggering of ventricular tachycardia by meteorologic and emotional stress: protective effect of beta-blockers and anxiolytics in men and elderly. American Journal of Epidemiology, 160, 1047–58.Google Scholar
Dannon, P. N., Sasson, Y., Hirschmann, S.et al. (2000). Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial. European Neuropsychopharmacology, 10, 165–9.CrossRefGoogle Scholar
Durel, L. A., Krantz, D. S., Eisold, J. F.et al. (1985). Behavioral effects of beta blockers: reduction of anxiety, acute stress, and type A behavior. Journal of Cardiopulmonary Rehabilitation, 5, 267–73.Google Scholar
Elliott, H. W. & Reifler, B. (2000). Social anxiety disorder. A guide for primary care physicians. North Carolina Medical Journal, 61, 176–8.Google Scholar
Elman, M. J., Sugar, J., Fiscella, R.et al. (1998). The effect of propranolol versus placebo on resident surgical performance. Transactions of the American Ophthalmological Society, 96, 283–91; discussion 291–4.Google Scholar
Fedorets, V. N., Radchenko, V. G. & Skoromets, A. A. (2004). Psychosomatic aspects of therapy in patients with ischemic heart disease of behavioral type A. Klinicheskaia Meditsina, 82, 54–6.Google Scholar
Frishman, W. H. (1980). Clinical pharmacology of the beta-adrenoreceptor blocking drugs. New York: Appleton Century-Crofts.
Frishman, W. H., Razin, A., Swencionis, C.et al. (1981). Beta-adrenoreceptor blockade in anxiety states: New approaches to therapy?Cardiovascular Reviews & Reports, 2, 447–59.Google Scholar
Granville-Grossman, K. & Turner, P. (1966). The effect of propranolol on anxiety. Lancet, 1, 788.CrossRefGoogle Scholar
Head, A., Kendall, M. J., Ferner, R. & Eagles, C. (1996). Acute effects of beta blockade and exercise on mood and anxiety. British Journal of Sports Medicine, 30, 238–42.CrossRefGoogle Scholar
Hirschmann, S., Dannon, P. N., Iancu, I.et al. (2000). Pindolol augmentation in patients with treatment-resistant panic disorder: a double-blind, placebo-controlled trial. Journal of Clinical Psychopharmacology, 20, 556–9.CrossRefGoogle Scholar
Kampman, K. M., Volpicelli, J. R., Mulvaney, F.et al. (2001). Effectiveness of propranolol for cocaine dependence treatment may depend on cocaine withdrawal symptom severity. Drug and Alcohol Dependence, 63, 69–78.Google Scholar
Keller, S. & Frishman, W. H. (2003). Neuropsychiatric effects of cardiovascular drug therapy. Cardiology in Review, 11, 73–93.CrossRefGoogle Scholar
Krantz, D. S., Contrada, R. J., Durel, L. A.et al. (1988). Comparative effects of two beta-blockers on cardiovascular reactivity and type A behavior in hypertensives. Psychosomatic Medicine, 50, 615–26.CrossRefGoogle Scholar
Krantz, D. S. & Durel, L. A. (1983). Psychobiological substrates of the type A behavior pattern. Health Psychology, 2, 393–411.CrossRefGoogle Scholar
Krantz, D. S., Durel, L. A., Davia, J. E.et al. (1982). Propranolol medication among coronary patients: relationship to type A behavior and cardiovascular response. Journal of Human Stress, 8, 4–12.CrossRefGoogle Scholar
Middlemiss, D. N., Buxton, D. A. & Greenwood, D. T. (1981). Beta-adrenoceptor antagonists in psychiatry and neurology. Pharmacological Therapy, 12, 419–37.Google Scholar
Moss, H. B. & Procci, W. R. (1982). Sexual dysfunction associated with oral hypertensive medications: a critical survey of the literature. General Hospital Psychiatry, 4, 121–9.Google Scholar
Neftel, K. A., Adler, R. H., Kapelli, L.et al. (1982). Stage fright in musicians: a model illustrating the effect of beta-blockers. Psychosomatic Medicine, 44, 461–9.CrossRefGoogle Scholar
Noyes, R. (1982). Beta-blocking drugs and anxiety. Psychosomatics, 23, 155–70.CrossRefGoogle Scholar
Patel, I. & Turner, P. (1981). Central action of beta-adrenoceptor blocking drugs in man. Medical Research Review, 1, 387–410.Google Scholar
Schmeider, R., Friedrich, G., Neus, H.et al. (1983). The influence of beta-blockers on cardiovascular reactivity and type A behavior pattern in hypertensives. Psychosomatic Medicine, 45, 417–23.CrossRefGoogle Scholar
Sokolski, K. N., Conney, J. C., Brown, B. J. & DeMet, E. M. (2004). Once-daily high-dose pindolol for SSRI-refractory depression. Psychiatry Research, 125, 81–6.Google Scholar
Swartz, C. M. (1998). Betaxolol in anxiety disorders. Annals of Clinical Psychiatry: Official Journal of the American Academy of Clinical Psychiatrists, 10, 9–14.Google Scholar
Taylor, F. & Cahill, L. (2002). Propranolol for reemergent posttraumatic stress disorder following an event of retraumatization: a case study. Journal of Traumatic Stress, 15, 433–7.Google Scholar
Tyrer, P. J. (1976). The role of bodily feelings in anxiety. London: Oxford University Press.
Vaiva, G., Ducrocq, F., Jezequel, K.et al. (2003). Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma. Biological Psychiatry, 54, 947–9.CrossRefGoogle Scholar
Weiner, N. (1985). Drugs that inhibit adrenergic nerves and block adrenergic receptors. In Goodman-Gilman, A. G., Goodman, L. S. & Gilman, A. (Eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics (7th edn.) (pp. 181–214). New York: Macmillan.

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×